Get the Stockscreener App
3.05
0.65%
-0.02
Galmed Pharmaceuticals Ltd stock is traded at $3.05, with a volume of 72,111.
It is down -0.65% in the last 24 hours and up +3.04% over the past month.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.
See More
Previous Close:
$3.07
Open:
$3.28
24h Volume:
72,111
Relative Volume:
0.08
Market Cap:
$5.05M
Revenue:
-
Net Income/Loss:
$-6.91M
P/E Ratio:
-0.4559
EPS:
-6.69
Net Cash Flow:
$-6.14M
1W Performance:
+2.69%
1M Performance:
+3.04%
6M Performance:
-19.72%
1Y Performance:
-36.43%
1-Day Range:
$2.89
$3.318
1-Week Range:
$2.8101
$3.39
52-Week Range:
$2.56
$23.80
Galmed Pharmaceuticals Ltd Stock (GLMD) Company Profile
Name
Galmed Pharmaceuticals Ltd
Sector
Industry
Phone
-
Address
-
Compare GLMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLMD
Galmed Pharmaceuticals Ltd
|
3.05 | 5.05M | 0 | -6.91M | -6.14M | -3.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Galmed Pharmaceuticals Ltd Stock (GLMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-22-20 | Downgrade | B. Riley FBR | Buy → Neutral |
| Feb-04-20 | Initiated | Craig Hallum | Buy |
| Jan-30-20 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-02-19 | Initiated | Canaccord Genuity | Buy |
| Dec-12-18 | Initiated | B. Riley FBR | Buy |
| Aug-02-18 | Reiterated | Maxim Group | Buy |
| Jul-13-18 | Initiated | Stifel | Buy |
| Jul-12-18 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-12-18 | Reiterated | H.C. Wainwright | Buy |
| Mar-15-18 | Upgrade | Maxim Group | Hold → Buy |
| Feb-14-18 | Downgrade | Maxim Group | Buy → Hold |
| Feb-12-18 | Reiterated | H.C. Wainwright | Buy |
| Nov-15-17 | Initiated | ROTH Capital | Buy |
| Aug-08-17 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-17 | Reiterated | Maxim Group | Buy |
| Aug-01-16 | Reiterated | Maxim Group | Buy |
| Jul-06-16 | Resumed | ROTH Capital | Buy |
| Mar-28-16 | Resumed | H.C. Wainwright | Buy |
| Jun-23-15 | Initiated | H.C. Wainwright | Buy |
| May-06-15 | Initiated | Sun Trust Rbsn Humphrey | Buy |
View All
Galmed Pharmaceuticals Ltd Stock (GLMD) Latest News
Galmed Phar stock hits 52-week low at $2.6 amid market challenges - Investing.com Nigeria
Galmed Phar stock hits 52-week low at $2.6 amid market challenges By Investing.com - Investing.com South Africa
Galmed Phar stock hits 52-week low at $2.71 amid market challenges By Investing.com - Investing.com South Africa
Galmed Phar stock hits 52-week low at $2.71 amid market challenges - Investing.com Nigeria
Galmed Pharmaceuticals: Q3 Earnings Snapshot - New Haven Register
Galmed Pharmaceuticals Embraces Market with New Sales Agreement - TipRanks
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Galmed Phar stock hits 52-week low at $2.73 amid challenges - Investing.com Australia
500: Something went wrong - Investing.com Canada
Galmed Pharmaceuticals Amends Equity Purchase Agreement - TipRanks
Acyl CoA Desaturase Market Current Status and Future Prospects - IndiaPolitics.com
galmed pharmaceuticals ltd. Earnings dates - RTTNews
Galmed Pharmaceuticals (NASDAQ:GLMD) Stock Passes Above 50-Day Moving Average of $4.52 - Defense World
United States shares lower at close of trade; Dow Jones Industrial Average down 0.25% - MSN
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.25% - MSN
(GLMD) Long Term Investment Analysis - Stock Traders Daily
Galmed reports positive results for Aramchol in NASH study By Investing.com - Investing.com Australia
Galmed reports positive results for Aramchol in NASH study - Investing.com India
Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology - PR Newswire
Post-Trade Analysis: Galmed Pharmaceuticals Ltd (GLMD) Slides -13.90, Closing at 8.05 - The Dwinnex
Take off with Galmed Pharmaceuticals Ltd (GLMD): Get ready for trading - SETE News
Understanding GLMD stock ratios for better investment decisions - US Post News
GLMD’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Optimistic Market Report Drives Galmed Pharmaceuticals (GLMD) Stock Upward - Stocks Telegraph
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs - GlobeNewswire
Galmed Pharmaceuticals Calls for Capital Increase Vote - TipRanks
Galmed expands drug development to cancer and heart diseases - Investing.com
Galmed surges on plans to expand into cancer and heart disease drug development - XM
Galmed Pharmaceuticals Stock Is Soaring Thursday: Here's Why - Benzinga
Market Insights: Galmed Pharmaceuticals Ltd (GLMD)’s Notable Drop of -54.30, Closing at 6.90 - The Dwinnex
Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases - PR Newswire
B. Riley FBR Downgrades Galmed Pharmaceuticals Ltd (GLMD) to a Neutral from a Buy - Knox Daily
Galmed Pharmaceuticals Down 53%, But Still Well Above Monday Closing Price - MarketWatch
US Stocks Mixed; General Mills Posts Upbeat Earnings - Benzinga
A new trading data show Galmed Pharmaceuticals Ltd (GLMD) is showing positive returns. - SETE News
Galmed Pharmaceuticals Soars Nearly 500% Amid Nasdaq Compliance and Short Squeeze - TipRanks
Those who invested in Neuren Pharmaceuticals (ASX:NEU) three years ago are up 576% - Yahoo Finance
Galmed Pharmaceuticals Surges 400%: What's Behind the Explosion? - MarketBeat
Gold Edges Lower; US Homebuilder Sentiment Rises For September - Benzinga
Galmed Pharmaceuticals Surges After Regaining Nasdaq Compliance - MarketWatch
Galmed Pharmaceuticals Ltd’s Banking’s 100-Day Moving Average at 4.01: Will the Stock Break Through? - The InvestChronicle
Stock Market news: Galmed Pharmaceuticals soars 283%, Intel up 3.49%, while Tupperware plunges 57% - Business Upturn
Express Scripts sues FTC and demands drug pricing report retraction - Yahoo! Voices
With its newest mac and cheese, Stouffer's expands beyond the freezer aisle to supermarket shelves - Yahoo! Voices
Merit Medical touts positive six-month data from WAVE trial - Yahoo! Voices
Lunds & Byerlys digitizes refrigeration compliance management - Yahoo! Voices
Galmed Pharmaceuticals Ltd Stock (GLMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):